Neuramedy conducts research on neurodegenerative disorders, specifically targeting alpha-synuclein and TLR2 to prevent its propagation and associated neuroinflammation in Parkinson's disease. The company collaborates with industry and academia to develop therapeutic solutions that address the underlying mechanisms of these age-related conditions.
Funding
$6.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's disease and other neurodegenerative disorders lack effective treatments that address the underlying mechanisms driving disease progression. The propagation of alpha-synuclein and associated neuroinflammation, mediated by TLR2, contribute significantly to neuronal damage and disease severity in these conditions.
Solution
Neuramedy is developing disease-modifying therapeutics targeting alpha-synuclein propagation and TLR2-mediated neuroinflammation to combat neurodegenerative diseases, particularly Parkinson's disease. Their strategic approach aims to prevent the spread of alpha-synuclein, a key pathological hallmark, and reduce the resulting neuroinflammation that exacerbates neuronal damage. By focusing on these fundamental mechanisms, Neuramedy seeks to create solutions that slow or halt disease progression, offering a more effective approach to managing these debilitating conditions. The company is pursuing this through internal research and collaborations with industry and academic partners.
Target Audience
The primary target audience includes individuals suffering from Parkinson's disease and other age-related neurodegenerative disorders, as well as pharmaceutical companies and research institutions seeking novel therapeutic interventions.
Features
- Tomaralimab antibody targeting alpha-synuclein.
- NM-101/ NM-102 therapeutic candidates.
- Focus on preventing alpha-synuclein propagation.
- Modulation of TLR2-mediated neuroinflammation.